Thomas E. Ahlering, MD:
Dr. Ahlering is Vice-Chairman of the Department of Urology and Professor of Urology at the University of California, Irvine. He was formerly Chief of the Division of Urology from 1992 – 2002. He completed his residency in urology and his fellowship training in urologic oncology at the University of Southern California. He has pioneered innovations to the Indiana pouch and ileal neo-bladder reconstructions. Dr. Ahlering has received local, national, and international recognition for his expertise in urologic oncology. His research focuses on the invasion and metastasis of prostate cancer and development of minimally invasive radical prostectomy assisted by the da Vinci Surgical System. He has performed more than 700 robotic surgeries, including the first robotic prostatectomies in Denmark, Canada, and Australia. Dr. Ahlering is actively involved in research projects in prostate and bladder cancer, and has produced several publications and book chapters.
Gamal Ghoniem, MD:
Dr. Ghoniem is Professor of Urology at the University of California, Irvine. He is fellowship-trained in neurourology and female urology. Dr. Ghoniem was previously a full-time faculty member at the Cleveland Clinic. He has served as a consultant of the surgical treatment group of the International Consultation on Urinary Incontinence. Dr. Ghoniem has also been appointed by the NIH as the chairman for a review panel on incontinence. He has been a member of the SUFU executive committee and has served a three year term as chairman of the Research and Development Committee of the international Urogynecological Association (IUGA). Dr. Ghoniem has edited two books on female pelvic pathologies in addition to writing multiple book chapters and publications. His clinical interests include female urology, pelvic reconstructive surgery, and voiding dysfunction.
Edward Uchio, MD:
Dr. Uchio is a nationally recognized leader in the management of genitourinary malignancies. He completed fellowship in urologic oncology at the National Cancer Institute in Bethesda, Maryland. He has vast expertise in all areas of urologic oncology including advanced surgical treatment of prostate, renal, testis, and bladder cancers. He also actively uses laparoscopic, robotic, and minimally invasive techniques in addition to novel technologies only available in clinical trials. Dr. Uchio has presented internationally on the molecular basis of renal malignancies and is the author of numerous publications and book chapters on urologic cancers. He has also received numerous research grants and NIH funding for many of his oncologic research projects.
Roshan Patel, MD:
Dr. Patel joined the Department of Urology at the University of California, Irvine in 2016 as a fellow in Endourology under the mentorship of Dr. Ralph Clayman and Dr. Jamie Landman. His clinical practice emphasizes all aspects of minimally invasive Urology including robotic, laparoscopic, percutaneous, ureteroscopic and needle ablative surgeries. An innovative urologist and surgeon, Dr. Patel’s research interests include outcomes based studies on minimally invasive surgery for kidney cancer. Additionally, he has a strong focus in evaluating the methodology used in percutaneous surgery for large kidney stones with the goal of improving patient outcomes. Lastly, he actively leads projects in the endourology lab in evaluating new technology that may change the way surgery is practiced today.
Joshua Mauney Ph.D.:
Dr. Mauney is the inaugural chair holder of the Jerry D. Choate Presidential Endowed Chair in Urology Tissue Engineering. He joins us from Boston Children’s Hospital and Harvard Medical School bringing a decade of experience in development of medical devices, continuous funding from NIH, and >40 publications authored in international peer-reviewed journals. In particular, Dr. Mauney’s research focuses on the fabrication and evaluation of “off-the-shelf” grafts, from silkworm cocoons, for the reconstruction of hollow organs of the urinary tract, like the bladder, urethra, and ureter. These silk fibroin-based scaffolds have low immunogenicity polymers and high structural strength and elasticity. Therefore, can be tailored to mimic the structural and functional properties of native tissues, without eliciting adverse host immune responses.
Follow Us